Ubrogepant for the treatment of migraine
| Autor: | Fabiola Cipolla, Paolo Martelletti, Luana Lionetto, Giusy Ylenia Cisale, Matilde Capi, Martina Curto |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Pyridines
Calcitonin Gene-Related Peptide Migraine Disorders macromolecular substances Calcitonin gene-related peptide Pharmacology 03 medical and health sciences 0302 clinical medicine MK-1602 Calcitonin Gene-Related Peptide Receptor Antagonists Ubrogepant medicine Humans Pharmacology (medical) migraine Pyrroles CGRP Neurogenic inflammation CGRP receptor antagonists business.industry General Medicine medicine.disease gepants Nociception Treatment Outcome nervous system Migraine Clinical Trials Phase III as Topic Calcitonin 030220 oncology & carcinogenesis Neurovascular Disorder business 030217 neurology & neurosurgery |
| Zdroj: | Expert opinion on pharmacotherapy. 21(7) |
| ISSN: | 1744-7666 |
| Popis: | Migraine is a neurovascular disorder involving neurogenic inflammation and transmission of trigeminovascular nociceptive pathways mediated by Calcitonin Gene-Related Peptide (CGRP). Several small molecules antagonizing the CGRP receptor have been developed as migraine-specific acute medications. The CGRP receptor antagonist ubrogepant, also known as MK-1602, has been recently evaluated in phase III clinical trials for clinical efficacy and long-term safety as an abortive migraine treatment.This paper discusses the pharmacodynamics, pharmacokinetics, clinical efficacy, safety, and tolerability profile of ubrogepant for the acute treatment of migraine with or without aura.Ubrogepant, a selective CGRP antagonist belonging to the gepants family, has been evaluated in large short- and long-term Phases 2 and 3 clinical trials aimed to assess clinical efficacy and safety as acute migraine medication. It did not significantly affect liver function and was not associated with other serious adverse events. Long-term non-serious adverse events were similar between placebo and ubrogepant. The efficacy was evaluated in large placebo-controlled studies and ubrogepant 50 mg and 100 mg was superior, even if the therapeutic gain seems to be low. Nevertheless, the favorable safety profile compared to other abortive drugs makes ubrogepant a promising option for the acute treatment of migraine. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|